SEARCH

SEARCH BY CITATION

References

  • 1
    Heijboer H, Brandjes DPM, Boller HR, Sturk A, Ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep venous thrombosis. N Engl J Med 1990; 323: 15126.
  • 2
    Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Int Med 2001; 135: 36773.
  • 3
    Walker ID, Greaves M, Preston FE. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 51228.
  • 4
    Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsch J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial management of proximal venous thrombosis. N Eng J Med 1990; 322: 12604.
  • 5
    Schwartz RS, Bauer KA, Rosenberg RD, Kavanaugh EJ, Davies DC, Bogdanoff DA. Clinical experience with antithrombin III concentrate in treatment to congenital and acquired deficiency of antithrombin. Am J Med 1989; 87 (Suppl. 3B): 53S60S.
  • 6
    Menache D, O'Malley JP, Schorr JB, Wagner B, Williams C and the Cooperative Study Group. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Blood 1990; 75: 339.
  • 7
    Bucur SZ, Levy JH, Despotis GJ, Spiess BD, Hillyer CD. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998; 38: 48198.
  • 8
    Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992; 68: 628783.
  • 9
    Lechner K, Kyrle PA. Antithrombin III concentrates – are they clinically useful? Thromb Haemostas 1995; 73: 3408.
  • 10
    Hoffman DL. Purification and large-scale preparation of antithrombin III. Am J Med 1989; 87 (Suppl. 3B): 23S26S.
  • 11
    Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, Manavalen P, Ziomek C, Meade H, McPherson JM, Cole ES. Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood 1998; 91: 456171.
  • 12
    D'Angelo SV, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77: 41625.
  • 13
    Zauber NP, Stark MW. Successful warfarin anticoagulation despite protein C deficiency and a history of warfarin necrosis. Ann Int Med 1986; 104: 65960.
  • 14
    De Stefano V, Mastrangelo S, Schwarz HP, Pola P, Flore R, Bizzi B, Leone G. Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency. Thromb Haemost 1993; 70: 2479.
  • 15
    Schramm W, Spannagl M, Bauer KA, Rosenberg RD, Birkner B, Linnau Y, Schwarz HP. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermat 1993; 129: 7536.
  • 16
    Prandoni P, Lensing AWA, Cogo A, Cuppini S, Villalta S, Carta M, Cattclan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 17.
  • 17
    Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lators G, Nicol P. A comparison of six weeks with six months of oral anticoagulation after a first episode of venous thromboembolism. N Eng J Med 1995; 332: 16615.
  • 18
    Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, Eklund S-G, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E and the Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 3938.
  • 19
    Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, and the Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Eng J Med 2001; 345: 1659.
  • 20
    Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 9017.
  • 21
    Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 28002.
  • 22
    Simioni P, Prandoni P, Lensing AWA, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg506[RIGHTWARDS ARROW]Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399403.
  • 23
    Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, Stümpflen A, Schneider B, Lechner K, Kyrle PA. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999; 81: 147.
  • 24
    Eichinger S, Pabinger I, St Schneider B, Ompflen A, Hirschl M, Bialonczyk C, Melichart M, Rintelen C, Lechner K, Kyrle PA. The risk of recurrence of venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 6248.
  • 25
    Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81: 68490.
  • 26
    Margaglione M, D'Andrea G, Colaizzo D, Cappucci G, Del Popolo A, Brancaccio V, Ciampa A, Grandone E, Di Minno G. Coexistence of factor V Leiden and factor II, A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999; 82: 15837.
  • 27
    De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Leone G. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 8016.
  • 28
    Baglin C, Brown K, Luddington R, Baglin T. Risk of recurrent thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group. Br J Haematol 1998; 100: 7648.
  • 29
    Sarasin FP, Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of DVT. BMJ 1998; 316: 959.
  • 30
    Hille ET, Westendorp RG, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997; 89: 19637.
  • 31
    Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL, Cumming T, Arruda V, Hillarp A, Reny JL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism – pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Anal Venous Thromboembolism. Thromb Haemost 2001; 86: 80916.
  • 32
    Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 10315.
  • 33
    Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Jude B, Griffin JH, Aiach M, the French network on the behalf of INSERM. Incidence of activated protein C resistance caused by ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995; 86: 21924.
  • 34
    Van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdbury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 41721.
  • 35
    Zoller B, Berntsdotter A, De Frutos GP, Dahlbäck B. Resistance to activated protein C as an additional risk factor in hereditary deficiency of protein S. Blood 1995; 12: 351823.
  • 36
    Meinardi JR, Middeldorp S, De Kam PJ, Koopman MM, Van Pampus EC, Hamulyak K, Prins MH, Buller HR, Van Der Meer J. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002; 116: 62531.
  • 37
    Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphosholipid–antibody syndrome. N Engl J Med 1995; 332: 9937.
  • 38
    Schulman S, Svenungsson E, Granqvist S, Group AS. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 3328.
  • 39
    Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JGP, Büller HR. The incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved INR. A retrospective analysis. J Clin Oncol 2000; 18: 307883.
  • 40
    Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 34848.
  • 41
    Van Den Belt AG, Sanson BJ, Simioni P, Prandoni P, Büller HR, Girolami A, Prins MH. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Int Med 1997; 157: 222732.
  • 42
    Van Den Belt AG, Hutten BA, Prins MH, Bossuy PM. Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S – a decision analysis. Thromb Haemost 2000; 84: 75863.
  • 43
    Van Boven HH, Vandenbroucke JP, Westendorp RG, Rosendaal FR. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997; 77: 4525.
  • 44
    Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, for the PREVENT Investigators. Long-term, low-intensity warfarin for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 142534.
  • 45
    Eriksson HW, Wählander K, Lundstrom T, Billing Clason S, Schulman S. Investigators tTI. Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood 2002; 100: 81a.
  • 46
    Ginsberg JS, Bates SM. Management of venous thromboembolism during pregancy. J Thromb Haemost 2003; 1: 143542.
  • 47
    Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, Geerts W, Kovacs M, Weitz JI, Robinson KS, Whittom R, Couture G. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence Clot This Pregnancy Study Group. N Engl J Med 2000; 343: 143944.
  • 48
    Friederich PW, Sanson BJ, Simioni P, Zanardi S, Huisman MV, Kindt I, Prandoni P, Büller HR, Girolami A, Prins MH. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125: 95560.
  • 49
    McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, Conkie JA et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78: 11838.
  • 50
    Lindqvist PG, Svensson P, Marsl K, Grennert L, Luterkorf M, Dahlbäck B. Activated protein C resistance (FV.Q506) and pregnancy. Thromb Haemost 1999; 81: 5327.
  • 51
    Pabinger I, Nemes L, Rintelen C, Koder S, Lechler E, Loreth RM, Kyrlc PA, Scharrer I, Sas G, Lechner K, Mannhalter C, Ehrenforth S. Pregnancy-associated risk for venous thromboembolism and pregnancy. Hematol J 2000; 1: 3741.
  • 52
    Middeldorp S, Libourel EJ, Hamulyak K, Van der Meer J, Büller HR. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001; 113: 5535.
  • 53
    Lee RV. Thromboembolic disease and pregnancy: are all women equal? Ann Intern Med 1996; 125: 10013.
  • 54
    Conard J, Horellou MH, Van Dreden P, Lecompte T, Samama M. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 31920.
  • 55
    De Stefano V, Leone G, De Carolis S, Ferrelli R, Di Donfrancesco A, Moneta E, Bizzi B. Management of pregnancy in women with antithrombin III congenital defect: report of four cases. Thromb Haemost 1988; 59: 1936.
  • 56
    Ginsberg JS, Hirsh J. Anticoagulants during pregnancy. Annu Rev Med 1989; 40: 7986.
  • 57
    Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood 2002; 100: 34708.